Search
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026.
Adapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigationalOn December 8th, 2008, Galderma Labs gained FDA approval for Epiduo®, a 0.1% adapalene, 2.5% BPO combination gel.[L12873] … [A193518] Differin®, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution.
Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigational[A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … [L49776,L49781] The FDA approval was based on positive results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalCelcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.
Imidafenacin
go.drugbank.com/drugs/DB09262InvestigationalImidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the traden...
Mecasermin
go.drugbank.com/drugs/DB01277ApprovedInvestigationalMecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label].
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigational[A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612]
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]